|
1
|
Wang S, Feng Y, Swinnen J, Oyen R, Li Y
and Ni Y: Incidence and prognosis of liver metastasis at diagnosis:
A pan-cancer population-based study. Am J Cancer Res. 10:1477–1517.
2020.
|
|
2
|
Pavel M, Baudin E, Couvelard A, Krenning
E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B and Salazar R;
Barcelona Consensus Conference participant, : ENETS consensus
guidelines for the management of patients with liver and other
distant metastases from neuroendocrine neoplasms of foregut,
midgut, hindgut, and unknown primary. Neuroendocrinology.
95:157–176. 2012. View Article : Google Scholar
|
|
3
|
Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW,
Lin HC, Lee RC, Chiou YY, Lee FY and Huo TI: Performance status in
patients with hepatocellular carcinoma: Determinants, prognostic
impact, and ability to improve the Barcelona clinic liver cancer
system. Hepatology. 57:112–119. 2013. View Article : Google Scholar
|
|
4
|
Culine S, Kramar A, Saghatchian M, Bugat
R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A and Fizazi K;
French Study Group on Carcinomas of Unknown Primary, : Development
and validation of a prognostic model to predict the length of
survival in patients with carcinomas of an unknown primary site. J
Clin Oncol. 20:4679–4683. 2002. View Article : Google Scholar
|
|
5
|
Pugh RNH, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar
|
|
6
|
Conejo I, Guardascione MA, Tandon P,
Cachero A, Castellote J, Abraldes JG, Amitrano L, Genescà J and
Augustin S: Multicenter external validation of risk stratification
criteria for patients with variceal bleeding. Clin Gastroenterol
Hepatol. 16:132–139.e8. 2018. View Article : Google Scholar
|
|
7
|
Suddle A, Reeves H, Hubner R, Marshall A,
Rowe I, Tiniakos D, Hubscher S, Callaway M, Sharma D, See TC, et
al: British society of gastroenterology guidelines for the
management of hepatocellular carcinoma in adults. Gut.
73:1235–1268. 2024. View Article : Google Scholar
|
|
8
|
Rindi G, Mete O, Uccella S, Basturk O, La
Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M
and Asa SL: Overview of the 2022 WHO classification of
neuroendocrine neoplasms. Endocr Pathol. 33:115–154. 2022.
View Article : Google Scholar
|
|
9
|
Ni X, Wei Y, Li X, Pan J, Fang B, Zhang T,
Lu Y, Ye D and Zhu Y: From biology to the clinic-exploring liver
metastasis in prostate cancer. Nat Rev Urol. 21:593–614. 2024.
View Article : Google Scholar
|
|
10
|
Aggarwal R, Huang J, Alumkal JJ, Zhang L,
Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, et
al: Clinical and genomic characterization of treatment-emergent
small-cell neuroendocrine prostate cancer: A multi-institutional
prospective study. J Clin Oncol. 36:2492–2503. 2018. View Article : Google Scholar
|
|
11
|
Abida W, Cyrta J, Heller G, Prandi D,
Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen
EM, et al: Genomic correlates of clinical outcome in advanced
prostate cancer. Proc Natl Acad Sci USA. 116:11428–11436. 2019.
View Article : Google Scholar
|
|
12
|
Yao JL, Madeb R, Bourne P, Lei J, Yang X,
Tickoo S, Liu Z, Tan D, Cheng L, Hatem F, et al: Small cell
carcinoma of the prostate: An immunohistochemical study. Am J Surg
Pathol. 30:705–712. 2006. View Article : Google Scholar
|
|
13
|
Aparicio AM, Harzstark AL, Corn PG, Wen S,
Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, et al:
Platinum-based chemotherapy for variant castrate-resistant prostate
cancer. Clin Cancer Res. 19:3621–3630. 2013. View Article : Google Scholar
|
|
14
|
Szarvas T, Csizmarik A, Fazekas T, Hüttl
A, Nyirády P, Hadaschik B, Grünwald V, Püllen L, Jurányi Z, Kocsis
Z, et al: Comprehensive analysis of serum chromogranin A and
neuron-specific enolase levels in localized and
castration-resistant prostate cancer. BJU Int. 127:44–55. 2021.
View Article : Google Scholar
|
|
15
|
Haffner MC, Morris MJ, Ding CKC, Sayar E,
Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, et
al: Framework for the pathology workup of metastatic
castration-resistant prostate cancer biopsies. Clin Cancer Res.
31:466–4478. 2025. View Article : Google Scholar
|
|
16
|
Gagnon R, Kish EK, Cook S, Takemura K,
Cheng BYC, Bressler K, Heng DYC, Alimohamed N, Ruether D, Lee-Ying
RM, et al: Real-world clinical outcomes and prognostic factors in
neuroendocrine prostate cancer. Clin Genitourin Cancer.
23:1022742025. View Article : Google Scholar
|
|
17
|
Liu S, Alabi BR, Yin Q and Stoyanova T:
Molecular mechanisms underlying the development of neuroendocrine
prostate cancer. Semin Cancer Biol. 86:57–68. 2022. View Article : Google Scholar
|
|
18
|
Choi TW, Kim HC, Lee JH, Yu SJ, Kang B,
Hur S, Lee M, Jae HJ and Chung JW: The safety and clinical outcomes
of chemoembolization in child-pugh class C patients with
hepatocellular carcinomas. Korean J Radiol. 16:1283–1293. 2015.
View Article : Google Scholar
|
|
19
|
Aida Y, Nakazawa K, Shiozawa T, Ogawa R,
Kiwamoto T, Morishima Y, Sakamoto T, Sekine I and Hizawa N:
Small-Cell lung cancer treatment of newly diagnosed patients with
poor performance status. Case Rep Oncol. 12:613–620. 2019.
View Article : Google Scholar
|
|
20
|
Bahij R, Jeppesen SS, Olsen KE, Halekoh U,
Holmskov K and Hansen O: Outcome of treatment in patients with
small cell lung cancer in poor performance status. Acta Oncol.
58:1612–1617. 2019. View Article : Google Scholar
|
